Tempus AI (NasdaqGS:TEM) has launched a new AI-driven HRD-RNA algorithm aimed at improving cancer diagnostics. The company has entered a partnership with Median Technologies to bring advanced lung ...
Tempus AI launched its HRD-RNA algorithm, an AI-driven model for identifying Homologous Recombination Deficiency in cancer patients. The company also partnered with Median Technologies to integrate ...
Tempus AI’s fair value estimate has been trimmed slightly from US$87.92 to US$86.71 per share, a small adjustment that still matters if you are tracking valuation closely. That shift sits alongside ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results